{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:54:19Z","timestamp":1761598459155,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.trim.2022.101721","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T12:05:18Z","timestamp":1663675518000},"page":"101721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Stem cells as an ideal carrier for gene therapy: A new approach to the treatment of hepatitis C virus"],"prefix":"10.1016","volume":"75","author":[{"given":"Alireza","family":"Rafati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Esmaeili Gouvarchin Ghaleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afsaneh","family":"Azarabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmood Reza","family":"Masoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmira","family":"Afrasiab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akbar","family":"Ghorbani Alvanegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.trim.2022.101721_bb0005","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/liv.14324","article-title":"Global timing of hepatitis C virus elimination in high-income countries","volume":"40","author":"Razavi","year":"2020","journal-title":"Liver Int."},{"issue":"10","key":"10.1016\/j.trim.2022.101721_bb0010","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jama.2020.1123","article-title":"Screening for hepatitis C virus infection in adolescents and adults: US preventive services task force recommendation statement","volume":"323","author":"Owens","year":"2020","journal-title":"JAMA."},{"issue":"1","key":"10.1016\/j.trim.2022.101721_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-59397-2","article-title":"Single-molecular real-time deep sequencing reveals the dynamics of multi-drug resistant haplotypes and structural variations in the hepatitis C virus genome","volume":"10","author":"Yamashita","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.trim.2022.101721_bb0020","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036822","article-title":"Hepatitis C virus structure: defined by what it is not","volume":"10","author":"Dearborn","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"1","key":"10.1016\/j.trim.2022.101721_bb0025","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/vaccines8010090","article-title":"Hepatitis C virus vaccine: challenges and prospects","volume":"8","author":"Duncan","year":"2020","journal-title":"Vaccines"},{"issue":"22","key":"10.1016\/j.trim.2022.101721_bb0030","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00704-20","article-title":"Structure-based design of hepatitis C virus E2 glycoprotein improves serum binding and cross-neutralization","volume":"94","author":"Pierce","year":"2020","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.trim.2022.101721_bb0035","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1210\/clinem\/dgz241","article-title":"Hepatitis C virus infection of human thyrocytes: metabolic, hormonal, and immunological implications","volume":"105","author":"Hammerstad","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.trim.2022.101721_bb0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/jcm10020221","article-title":"Immunological mechanisms for hepatocellular carcinoma risk after direct-acting antiviral treatment of hepatitis C virus infection","volume":"10","author":"Sung","year":"2021","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.trim.2022.101721_bb0045","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036988","article-title":"Innate immunity in hepatitis C virus infection","volume":"11","author":"Schwerk","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"3","key":"10.1016\/j.trim.2022.101721_bb0050","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3390\/jcm9030790","article-title":"Hepatitis C virus: evading the intracellular innate immunity","volume":"9","author":"Ferreira","year":"2020","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.trim.2022.101721_bb0055","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/vaccines8020313","article-title":"Innate immune response against hepatitis C virus: targets for vaccine adjuvants","volume":"8","author":"Sepulveda-Crespo","year":"2020","journal-title":"Vaccines."},{"issue":"8","key":"10.1016\/j.trim.2022.101721_bb0060","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.4049\/jimmunol.2000376","article-title":"Tupaia MAVS is a dual target during hepatitis C virus infection for innate immune evasion and viral replication via NF-\u03baB","volume":"205","author":"Xu","year":"2020","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.trim.2022.101721_bb0065","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.3390\/ijms21072583","article-title":"Interferon response in hepatitis C virus-infected hepatocytes: issues to consider in the era of direct-acting antivirals","volume":"21","author":"Sung","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"37","key":"10.1016\/j.trim.2022.101721_bb0070","doi-asserted-by":"crossref","first-page":"13123","DOI":"10.1074\/jbc.RA120.014260","article-title":"N6-Methyladenosine modification of hepatitis B and C viral RNAs attenuates host innate immunity via RIG-I signaling","volume":"295","author":"Kim","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.trim.2022.101721_bb0075","first-page":"10","article-title":"Mitophagy and innate immunity in infection","volume":"43","author":"Cho","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.trim.2022.101721_bb0080","article-title":"CD4+ T cells: differentiation and functions","volume":"2012","author":"Rishi","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.trim.2022.101721_bb0085","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.antiviral.2014.11.009","article-title":"T cell responses in hepatitis C virus infection: historical overview and goals for future research","volume":"114","author":"Holz","year":"2015","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.trim.2022.101721_bb0090","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.vaccine.2018.11.024","article-title":"Interferon gamma (IFN-\u03b3) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigens","volume":"37","author":"Nakiboneka","year":"2019","journal-title":"Vaccine."},{"key":"10.1016\/j.trim.2022.101721_bb0095","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2014.00550","article-title":"The humoral immune response to HCV: understanding is key to vaccine development","volume":"5","author":"Cashman","year":"2014","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.trim.2022.101721_bb0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/v12010075","article-title":"Envelope-specific IgG3 and IgG1 responses are associated with clearance of acute hepatitis C virus infection","volume":"12","author":"Walker","year":"2020","journal-title":"Viruses."},{"issue":"1","key":"10.1016\/j.trim.2022.101721_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-020-00669-4","article-title":"Hepatitis C virus vaccine design: focus on the humoral immune response","volume":"27","author":"Sepulveda-Crespo","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.trim.2022.101721_bb0110","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3389\/fmicb.2020.576572","article-title":"Technical validation of a hepatitis C virus whole genome sequencing assay for detection of genotype and antiviral resistance in the clinical pathway","volume":"11","author":"Manso","year":"2020","journal-title":"Front. Microbiol."},{"issue":"12","key":"10.1016\/j.trim.2022.101721_bb0115","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/infdis\/jiaa037","article-title":"Time to detection of hepatitis C virus infection with the Xpert HCV viral load fingerstick point-of-care assay: facilitating a more rapid time to diagnosis","volume":"221","author":"Grebely","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.trim.2022.101721_bb0120","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4254\/wjh.v7.i5.725","article-title":"Hepatitis C virus: is it time to say goodbye yet? Perspectives and challenges for the next decade","volume":"7","author":"Barth","year":"2015","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.trim.2022.101721_bb0125","doi-asserted-by":"crossref","first-page":"16034","DOI":"10.1038\/mtm.2016.34","article-title":"Clinical development of gene therapy: results and lessons from recent successes","volume":"3","author":"Kumar","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"1","key":"10.1016\/j.trim.2022.101721_bb0130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/humc.2014.155","article-title":"Dog models for blinding inherited retinal dystrophies","volume":"26","author":"Petersen-Jones","year":"2015","journal-title":"Hum. Gene Ther. Clin. Dev."},{"issue":"6","key":"10.1016\/j.trim.2022.101721_bb0135","first-page":"531","article-title":"Contemporary animal models for human gene therapy applications","volume":"15","author":"Gopinath","year":"2015","journal-title":"Gene Ther."},{"issue":"2 (5)","key":"10.1016\/j.trim.2022.101721_bb0140","article-title":"Induced pluripotent stem cells: problems and advantages when applying them in regenerative medicine","volume":"2","author":"Medvedev","year":"2010","journal-title":"Acta Nat."},{"issue":"1","key":"10.1016\/j.trim.2022.101721_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/0971-6866.112870","article-title":"Delivery systems for gene therapy","volume":"19","author":"Mali","year":"2013","journal-title":"Indian J. Hum. Genet."},{"key":"10.1016\/j.trim.2022.101721_bb0150","first-page":"1","article-title":"Therapeutic proteins","author":"Dimitrov","year":"2012","journal-title":"Ther. Prot."},{"issue":"5","key":"10.1016\/j.trim.2022.101721_bb0155","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.trim.2022.101721_bb0160","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/diseases6020042","article-title":"Viral vectors in gene therapy","volume":"6","author":"Lundstrom","year":"2018","journal-title":"Diseases"},{"issue":"44","key":"10.1016\/j.trim.2022.101721_bb0165","first-page":"42","article-title":"Reverse genetics approaches of Borna disease virus: applications in development of viral vectors and preventive vaccines","author":"Komatsu","year":"2020","journal-title":"Curr. Opin. Microbiol."},{"issue":"4","key":"10.1016\/j.trim.2022.101721_bb0170","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01206-20","article-title":"Selection for reducing energy cost of protein production drives the GC content and amino acid composition bias in gene transfer agents","volume":"11","author":"Kogay","year":"2020","journal-title":"Mbio."},{"key":"10.1016\/j.trim.2022.101721_bb0175","article-title":"Genetic engineering as a strategy to improve the therapeutic efficacy of mesenchymal stem\/stromal cells in regenerative medicine. Front cell","volume":"8","author":"Damasceno","year":"2020","journal-title":"Dev. Biol."},{"issue":"2","key":"10.1016\/j.trim.2022.101721_bb0180","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150025","article-title":"Human mesenchymal stem cells-current trends and future prospective","volume":"35","author":"Ullah","year":"2015","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.trim.2022.101721_bb0185","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev-bioeng-070909-105309","article-title":"Mesenchymal stem cells as therapeutics","volume":"12","author":"Parekkadan","year":"2010","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.trim.2022.101721_bb0190","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3389\/fimmu.2017.01770","article-title":"Mesenchymal stromal\/stem cells: a new era in the cell-based targeted gene therapy of cancer","volume":"8","author":"Marofi","year":"2017","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.trim.2022.101721_bb0195","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jcyt.2016.09.003","article-title":"Genetically modified mesenchymal stromal cells in cancer therapy","volume":"18","author":"Sage","year":"2016","journal-title":"Cytotherapy."},{"key":"10.1016\/j.trim.2022.101721_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119087","article-title":"Recent trends in cancer therapy: a review on the current state of gene delivery","author":"Yahya","year":"2021","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.trim.2022.101721_bb0205","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3390\/cancers12051139","article-title":"Expanding the spectrum of adenoviral vectors for cancer therapy","volume":"12","author":"Gao","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.trim.2022.101721_bb0210","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omto.2021.01.015","article-title":"Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35","volume":"20","author":"Ono","year":"2021","journal-title":"Mol. Ther. Oncol."},{"issue":"12","key":"10.1016\/j.trim.2022.101721_bb0215","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1517\/14712598.5.12.1571","article-title":"Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases","volume":"5","author":"Reiser","year":"2005","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.trim.2022.101721_bb0220","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.toxlet.2019.11.006","article-title":"HepG2-1A2 C2 and C7: lentivirus vector-mediated stable and functional overexpression of cytochrome P450 1A2 in human hepatoblastoma cells","volume":"319","author":"Steinbrecht","year":"2020","journal-title":"Toxicol. Lett."},{"issue":"12","key":"10.1016\/j.trim.2022.101721_bb0225","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1002\/bit.27540","article-title":"Alteration of gammaretroviral vector integration patterns by insertion of histone and leucine zipper into integrase","volume":"117","author":"Yang","year":"2020","journal-title":"Biotechnol. Bioeng."},{"issue":"6","key":"10.1016\/j.trim.2022.101721_bb0230","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/v12060668","article-title":"Adeno-associated virus (AAV) capsid stability and liposome remodeling during endo\/lysosomal pH trafficking","volume":"12","author":"Lins-Austin","year":"2020","journal-title":"Viruses."},{"issue":"12","key":"10.1016\/j.trim.2022.101721_bb0235","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.3390\/molecules25122866","article-title":"Role of lipid-based and polymer-based non-viral vectors in nucleic acid delivery for next-generation gene therapy","volume":"25","author":"Wahane","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.trim.2022.101721_bb0240","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.adgen.2014.11.001","article-title":"Nonviral gene delivery systems by the combination of bubble liposomes and ultrasound","volume":"89","author":"Omata","year":"2015","journal-title":"Adv. Genet."},{"key":"10.1016\/j.trim.2022.101721_bb0245","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3389\/fimmu.2017.01770","article-title":"Mesenchymal stromal\/stem cells: a new era in the cell-based targeted gene therapy of cancer","volume":"8","author":"Marofi","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trim.2022.101721_bb0250","article-title":"Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics","volume":"118588","author":"Yadav","year":"2020","journal-title":"Life Sci."},{"issue":"9","key":"10.1016\/j.trim.2022.101721_bb0255","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/sctm.18-0024","article-title":"Concise review: mesenchymal stem cell-based drug delivery: the good, the bad, the ugly, and the promise","volume":"7","author":"Krueger","year":"2018","journal-title":"Stem Cells Transl. Med."},{"issue":"7","key":"10.1016\/j.trim.2022.101721_bb0260","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1593\/neo.12634","article-title":"Identification of cell surface targets through meta-analysis of microarray data","volume":"14","author":"Haeberle","year":"2012","journal-title":"Neoplasia."},{"issue":"2","key":"10.1016\/j.trim.2022.101721_bb0265","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/stem.3110","article-title":"Inherited cardiac diseases, pluripotent stem cells, and genome editing combined\u2014the past, present, and future","volume":"38","author":"van den Brink","year":"2020","journal-title":"Stem Cells"},{"key":"10.1016\/j.trim.2022.101721_bb0270","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9628536","article-title":"Challenges and controversies in human mesenchymal stem cell therapy","volume":"2019","author":"Lukomska","year":"2019","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.trim.2022.101721_bb0275","first-page":"1","article-title":"Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview","author":"Ali","year":"2020","journal-title":"Immunol. Res."},{"issue":"8","key":"10.1016\/j.trim.2022.101721_bb0280","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3390\/cells8080886","article-title":"Mesenchymal stem cells for regenerative medicine","volume":"8","author":"Han","year":"2019","journal-title":"Cells."},{"issue":"13","key":"10.1016\/j.trim.2022.101721_bb0285","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.2174\/1381612811319130015","article-title":"Mesenchymal stem\/stromal cells: a new \u201ccells as drugs\u201d paradigm. Efficacy and critical aspects in cell therapy","volume":"19","author":"de Girolamo","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.trim.2022.101721_bb0290","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3057624","article-title":"Mesenchymal stem cell-based immunomodulation: properties and clinical application","volume":"2018","author":"Wang","year":"2018","journal-title":"Stem Cells Int."},{"issue":"5","key":"10.1016\/j.trim.2022.101721_bb0295","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s12015-015-9605-9","article-title":"Practical issues with the use of stem cells for cancer gene therapy","volume":"11","author":"Nouri","year":"2015","journal-title":"Stem Cell Rev. Rep."},{"issue":"4","key":"10.1016\/j.trim.2022.101721_bb0300","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2567.2012.03590.x","article-title":"Dendritic cell-based immunity and vaccination against hepatitis C virus infection","volume":"136","author":"Zhou","year":"2012","journal-title":"Immunology."},{"key":"10.1016\/j.trim.2022.101721_bb0305","article-title":"Genetic lesions of type i interferon signalling in human antiviral immunity","author":"Duncan","year":"2020","journal-title":"Trends Genet."},{"issue":"1","key":"10.1016\/j.trim.2022.101721_bb0310","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4254\/wjh.v13.i1.109","article-title":"Association of interferon lambda-4 rs12979860 polymorphism with hepatocellular carcinoma in patients with chronic hepatitis C infection","volume":"13","author":"de Bitencorte","year":"2021","journal-title":"World J. Hepatol."},{"issue":"8","key":"10.1016\/j.trim.2022.101721_bb0315","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3389\/fimmu.2017.01707","article-title":"Interferon lambda genetics and biology in regulation of viral control","author":"Hemann","year":"2017","journal-title":"Front. Immunol."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422001952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422001952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:03:05Z","timestamp":1760810585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327422001952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":63,"alternative-id":["S0966327422001952"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2022.101721","relation":{},"ISSN":["0966-3274"],"issn-type":[{"type":"print","value":"0966-3274"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stem cells as an ideal carrier for gene therapy: A new approach to the treatment of hepatitis C virus","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2022.101721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101721"}}